TL;DR: Aetna, a CVS Health company, modified CPB 0562 covering biochemical markers of bone remodeling, effective September 26, 2025. Here's what billing teams need to do.
This update to the Aetna biochemical markers of bone remodeling coverage policy touches 19 CPT codes — including CPT 82523, 83937, 84075–84080, and 77080 — and 27 ICD-10-CM diagnosis codes across a broad range of metabolic bone conditions. If your practice or lab bills bone remodeling marker tests for osteoporosis monitoring, renal osteodystrophy, or prosthetic joint management, this policy revision affects your reimbursement. CPB 0562 Aetna governs coverage determinations for these markers, and the September 26, 2025 effective date is now in play.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Biochemical Markers of Bone Remodeling |
| Policy Code | CPB 0562 |
| Change Type | Modified |
| Effective Date | September 26, 2025 |
| Impact Level | Medium |
| Specialties Affected | Endocrinology, Nephrology, Rheumatology, Orthopedic Surgery, Clinical Laboratory |
| Key Action | Audit your ICD-10 pairings for CPT 82523, 83937, and 84075–84080 against updated medical necessity criteria before billing under this policy |
Aetna Biochemical Markers of Bone Remodeling Coverage Criteria and Medical Necessity Requirements 2025
The Aetna biochemical markers of bone remodeling coverage policy ties reimbursement directly to documented medical necessity. Aetna covers these markers when specific clinical conditions and patient criteria are met. Without the right diagnosis codes linked to the right CPT codes, you're looking at a claim denial.
The policy addresses several distinct covered indications. Bone remodeling marker testing is covered for managing age-related osteoporosis — ICD-10 codes M80.00XA through M81.8 — and for patients with chronic kidney disease (N18.1–N18.9) at risk for renal osteodystrophy. Patients with osteogenesis imperfecta (Q78.0) also fall within covered territory.
Two ICD-10 pairings stand out as situational. The policy covers alkaline phosphatase testing — CPT 84075 through 84080 — specifically for evaluating children and adolescents with secondary osteoporosis. That age restriction is explicit. Bill these codes for adults without documented secondary osteoporosis and you're building a denial.
Patients receiving serotonergic antidepressants also get coverage consideration. Major depressive disorder codes F32.0–F33.9, paired with renal osteodystrophy diagnosis N25.0, are listed together under the same covered group. This is an unusual pairing. It reflects documented evidence that serotonergic antidepressants affect bone density. Make sure your clinical documentation captures the medication history when you bill this combination.
Prior authorization requirements for biochemical bone marker testing under Aetna vary by plan. Check the member's specific plan benefits before assuming these markers are covered without prior auth. Commercial plans and self-funded plans often differ from standard Aetna billing guidelines.
The policy also covers bone marker testing in the context of mechanical loosening of internal prosthetic joints (T84.030A–T84.039S) and periprosthetic osteolysis (T84.050A–T84.058S). Orthopedic practices billing for bone turnover markers post-joint replacement should map these ICD-10 codes carefully.
Aetna Biochemical Markers of Bone Remodeling Exclusions and Non-Covered Indications
The policy has at least one explicit non-coverage note worth flagging. CPT 88319 — special stain for enzyme constituents, including tartrate-resistant acid phosphatase — falls under the covered code list but carries restrictions based on indication. Bill this code outside the covered indications and Aetna will deny it.
The osteonecrosis of the jaw indication — ICD-10 M87.08 — is listed as not covered for evaluating risk of developing this condition. The brackets in the policy data say it directly: "[not covered for evaluating risk of developing...]." If a prescriber wants bone markers to screen for ONJ risk in a patient on bisphosphonates, Aetna's coverage policy does not support that claim. This is a specific clinical scenario that comes up in oncology and oral surgery billing. Document it clearly and communicate the non-coverage to patients before the test is ordered.
Asymptomatic menopausal state (Z78.0) is listed as a covered diagnosis for bone marker testing, but it must meet the broader medical necessity criteria. Billing Z78.0 alone, without additional clinical justification documented in the record, is a denial risk. The same logic applies to Z13.820 — encounter for osteoporosis screening. Screening alone may not satisfy medical necessity for the full panel of biochemical markers listed here.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Age-related osteoporosis (with or without pathological fracture) | Covered | M80.00XA–M81.8, CPT 82523, 83937, 83500, 83505 | Confirm plan-level prior auth requirements |
| Chronic kidney disease (stages 1–5 and ESRD) | Covered | N18.1–N18.9, CPT 83937, 84075–84080 | CKD-related bone disease must be documented |
| Renal osteodystrophy in patients on serotonergic antidepressants | Covered | N25.0, F32.0–F33.9, CPT 82523 | Medication history must support the diagnosis pairing |
| Secondary osteoporosis — children and adolescents | Covered | CPT 84075–84080 | Age restriction applies; adult billing without secondary osteoporosis diagnosis will deny |
| Osteogenesis imperfecta | Covered | Q78.0, CPT 82523, 83937 | Rare condition; confirm documentation supports diagnosis |
| Mechanical loosening of internal prosthetic joint | Covered | T84.030A–T84.039S, CPT 82523, 88319 | Post-arthroplasty monitoring context |
| Periprosthetic osteolysis of internal prosthetic joint | Covered | T84.050A–T84.058S, CPT 82523 | Must document osteolysis, not just joint pain |
| Charcot's joint, ankle and foot | Covered | M14.671–M14.679, CPT 83937, 84075 | Bilateral site specificity codes apply |
| Asymptomatic menopausal state | Covered (with criteria) | Z78.0 | Medical necessity documentation required beyond menopausal status alone |
| Osteoporosis screening encounter | Covered (with criteria) | Z13.820 | Screening alone may be insufficient for full biochemical panel |
| Osteonecrosis of jaw — risk evaluation | Not Covered | M87.08 | Explicitly excluded for risk-of-developing indication |
| Bone mineral density studies | Related | CPT 76977, 77078, 77080, 77081 | Listed as related CPT codes; coverage determined separately by bone density policy |
Aetna Bone Remodeling Marker Billing Guidelines and Action Items 2025
The effective date is September 26, 2025. These action items should already be in motion.
| # | Action Item |
|---|---|
| 1 | Audit your ICD-10 pairings for CPT 84075–84080 now. These alkaline phosphatase codes are covered only for children and adolescents with secondary osteoporosis. Pull your claims from the past 90 days. If you billed these codes for adult patients without secondary osteoporosis documentation, check whether those claims are at risk for retroactive review. |
| 2 | Update your charge capture for the serotonergic antidepressant bone marker indication. When you bill N25.0 with F32.0–F33.9, the clinical record must document the patient is actively receiving a serotonergic antidepressant. Build a documentation checklist into your ordering workflow for this combination. |
| 3 | Flag M87.08 as a non-covered diagnosis for biochemical bone marker testing. Update your billing system to prevent CPT codes under CPB 0562 from being submitted with M87.08 when the indication is ONJ risk evaluation. An automated edit will save you the denial and the appeal. |
| 4 | Verify prior authorization requirements for each commercial plan. Biochemical bone remodeling marker billing under Aetna commercial plans is not uniform. Check the member's certificate of coverage and prior auth list before ordering CPT 82523, 83529, or 83937 on new patients. One phone call now beats a denial appeal in 60 days. |
| 5 | Review your coding for CPT 83529 (Interleukin-6) and CPT 83090 (Homocysteine). These codes appear in the policy but are not mainstream bone remodeling markers. If your practice orders them in the context of bone disease, make sure the clinical documentation explicitly connects the test to a covered indication under CPB 0562. Aetna's medical necessity review will look for that connection. |
| 6 | Separate DXA and bone density imaging claims from biochemical marker claims. CPT 77080, 77081, 76977, and 77078 are listed as related codes — not covered under CPB 0562 directly. Bone mineral density testing has its own coverage policy. Don't let a bundling question create a denial on either claim. |
If your practice bills a high volume of bone remodeling markers — especially in nephrology or endocrinology — talk to your compliance officer before the end of Q3 2025. The ICD-10 specificity requirements here are tight, and a coverage audit would find loose documentation fast.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Biochemical Markers of Bone Remodeling Under CPB 0562
Covered CPT Codes (When Medical Necessity Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 82523 | CPT | Collagen cross links, any method |
| 82607 | CPT | Cyanocobalamin (Vitamin B-12) |
| 82608 | CPT | Cyanocobalamin (Vitamin B-12); unsaturated binding capacity |
| 83090 | CPT | Homocysteine |
| 83500 | CPT | Hydroxyproline; free |
| 83505 | CPT | Hydroxyproline; total |
| 83529 | CPT | Interleukin-6 (IL-6) |
| 83937 | CPT | Osteocalcin (bone Gla protein) |
| 84075 | CPT | Phosphatase, alkaline [children/adolescents with secondary osteoporosis] |
| 84076 | CPT | Phosphatase, alkaline [children/adolescents with secondary osteoporosis] |
| 84077 | CPT | Phosphatase, alkaline [children/adolescents with secondary osteoporosis] |
| 84078 | CPT | Phosphatase, alkaline [children/adolescents with secondary osteoporosis] |
| 84079 | CPT | Phosphatase, alkaline [children/adolescents with secondary osteoporosis] |
| 84080 | CPT | Phosphatase, alkaline [children/adolescents with secondary osteoporosis] |
| 88319 | CPT | Special stain including interpretation and report; Group III, for enzyme constituents (tartrate-resistant) |
Other CPT Codes Related to CPB 0562 (Coverage Determined Separately)
| Code | Type | Description |
|---|---|---|
| 76977 | CPT | Ultrasound bone density measurement and interpretation, peripheral site(s), any method |
| 77078 | CPT | Computed tomography, bone mineral density study, one or more sites |
| 77080 | CPT | Dual energy X-ray absorptiometry (DXA), bone density study, one or more sites |
| 77081 | CPT | Dual energy X-ray absorptiometry (DXA), bone density study, one or more sites |
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| F32.0–F33.9 | Major depressive disorder [for persons receiving serotonergic antidepressants] |
| M14.671–M14.679 | Charcot's joint, ankle and foot (site-specific laterality codes) |
| M80.00XA–M81.8 | Age-related osteoporosis with or without current pathological fracture |
| M87.08 | Idiopathic aseptic necrosis of bone, other site — jaw [NOT covered for evaluating risk of developing ONJ] |
| N18.1–N18.9 | Chronic kidney disease (CKD), stages 1–5, unspecified, and ESRD |
| N25.0 | Renal osteodystrophy [for persons receiving serotonergic antidepressants] |
| Q78.0 | Osteogenesis imperfecta |
| T84.030A–T84.039S | Mechanical loosening of internal prosthetic joint |
| T84.050A–T84.058S | Periprosthetic osteolysis of internal prosthetic joint |
| Z13.820 | Encounter for screening for osteoporosis |
| Z78.0 | Asymptomatic menopausal state |
Get the Full Picture for CPT 82523
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.